Literature DB >> 18274296

Histone H1 interacts preferentially with DNA fragments containing a cisplatin-induced 1,2-intrastrand cross-link.

Julia N Yaneva1, Elena G Paneva, Siyka I Zacharieva, Jordanka Zlatanova.   

Abstract

Cisplatin [cis-diamminedichloroplatinum(II) or cis-DDP], but not its stereoisomer transplatin, is suggested to be among the most powerful anticancer agents. It is believed that its therapeutic activity results from its interaction with DNA forming intra- and interstrand crosslinks. During our earlier investigations, we have observed a prominent preference of the linker histone H1 for binding to cis-platinated DNA (containing several different cross-links along the DNA fragment) compared with unmodified or transplatin-modified DNA. This report presents our recent experimental data obtained by band-shift analysis on the binding of H1 to a cisplatin-modified synthetic 34 bp DNA fragment containing a single target d(GG/CC) for 1,2 cis-intra-platination. Results obtained with another nuclear protein with similar DNA-binding properties, HMGB1, are also presented. The experimental data throw light on the precise preference of histone H1 for binding to different types of cisplatin-created cross-links in DNA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18274296     DOI: 10.1515/znc-2007-11-1220

Source DB:  PubMed          Journal:  Z Naturforsch C J Biosci        ISSN: 0341-0382


  1 in total

1.  Ethaselen: a novel organoselenium anticancer agent targeting thioredoxin reductase 1 reverses cisplatin resistance in drug-resistant K562 cells by inducing apoptosis.

Authors:  Suo-Fu Ye; Yong Yang; Lin Wu; Wei-Wei Ma; Hui-Hui Zeng
Journal:  J Zhejiang Univ Sci B       Date:  2017-05       Impact factor: 3.066

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.